Page 109 - IMO-1-1

Innovative Medicines & Omics SARS-CoV-2 inhibition by quinolines

CoV-2 variants. Indian J Med Res. 2023;158(3):257-268. 14. Shetty RM, Namachivayam A. Evidence for chloroquine/
hydroxychloroquine in the treatment of COVID-19. Indian
doi: 10.4103/ijmr.ijmr_2591_22
J Crit Care Med. 2021;25(4):441-452.
4. Xie X, Lan Q, Zhao J, et al. Structure-based design of pan-
coronavirus inhibitors targeting host cathepsin L and doi: 10.5005/jp-journals-10071-23773
calpain-1. Signal Transduct Target Ther. 2024;9(1):54. 15. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB,
doi: 10.1038/s41392-024-01758-8 Walsh SP, Meyerowitz-Katz G. Assessing the age specificity
of infection fatality rates for COVID-19: Systematic
5. Hillary VE, Ceasar SA. An update on COVID-19: SARS- review, meta-analysis, and public policy implications. Eur J
CoV-2 variants, antiviral drugs, and vaccines. Heliyon. Epidemiol. 2020;35(12):1123-1138.
2023;9(3):e13952.
doi: 10.1007/s10654-020-00698-1
doi: 10.1016/j.heliyon.2023.e13952
16. Sacramento CQ, Fintelman-Rodrigues N, Dias SS,
6. Alipoor R, Ranjbar R. Small-molecule metabolites in SARS- et al. Unlike chloroquine, mefloquine inhibits SARS-
CoV-2 treatment: A comprehensive review. Biol Chem. CoV-2 infection in physiologically relevant cells. Viruses.
2023;404(6):569-584. 2022;14(2):374.
doi: 10.1515/hsz-2022-0323 doi: 10.3390/v14020374
7. Zhu J, Zhang H, Lin Q, et al. Progress on SARS-CoV-2 3CLpro 17. Malakar S, Sreelatha L, Dechtawewat T, et al. Drug
Inhibitors: Inspiration from SARS-CoV 3CLpro repurposing of quinine as antiviral against dengue virus
peptidomimetics and small-molecule anti-inflammatory infection. Virus Res. 2018;255:171-178.
compounds. Drug Des Devel Ther. 2022;16:1067-1082.
doi: 10.1016/j.virusres.2018.07.018
doi: 10.2147/DDDT.S359009
18. Al-Bari MA. Targeting endosomal acidification by
8. Schimunek J, Seidl P, Elez K, et al. A community chloroquine analogs as a promising strategy for the
effort in SARS-CoV-2 drug discovery. Mol Inform. treatment of emerging viral diseases. Pharmacol Res
2024;43(1):e202300262. Perspect. 2017;5(1):e00293.
doi: 10.1002/minf.202300262 doi: 10.1002/prp2.293
9. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and 19. D’Alessandro S, Scaccabarozzi D, Signorini L, et al. The use
hydroxychloroquine in the treatment of COVID-19. Eur Rev of antimalarial drugs against viral infection. Microorganisms.
Med Pharmacol Sci. 2020;24(8):4539-4547. 2020;8(1):85.
doi: 10.26355/eurrev_202004_21038 doi: 10.3390/microorganisms8010085
10. Lin L, Lu L, Cao W, et al. Hypothesis for potential 20. Bazotte RB, Hirabara SM, Serdan TA, et al. 4-Aminoquinoline
pathogenesis of SARS-CoV-2 infection-a review of immune compounds from the Spanish flu to COVID-19. Biomed
changes in patients with viral pneumonia. Emerg Microbes Pharmacother. 2021;135:111138.
Infect. 2020;9(1):727-732.
doi: 10.1016/j.biopha.2020.111138
doi: 10.1080/22221751.2020.1746199
21. Mizuta S, Mosaddeque F, Tun MM, et al. Challenges
11. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity based on antiplasmodial and antiviral activities of
and projection of optimized dosing design of 7-chloro-4-aminoquinoline derivatives. ChemMedChem.
hydroxychloroquine for the treatment of severe acute 2023;18(7):e202200586.
respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin
Infect Dis. 2020;71(15):732-739. doi: 10.1002/cmdc.202200586
doi: 10.1093/cid/ciaa237 22. Belhassan A, En-Nahli F, Zaki H, Lakhlifi T, Bouachrine M.
Assessment of effective imidazole derivatives against SARS-
12. Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The CoV-2 main protease through computational approach. Life
possible mechanisms of action of 4-aminoquinolines Sci. 2020;262:118469.
(chloroquine/hydroxychloroquine) against SARS-Cov-2
infection (COVID-19): A role for iron homeostasis? doi: 10.1016/j.lfs.2020.118469
Pharmacol Res. 2020;158:104904. 23. O’Neill PM, Ward SA, Berry NG, et al. A medicinal
doi: 10.1016/j.phrs.2020.104904 chemistry perspective on 4-aminoquinoline antimalarial
drugs. Curr Top Med Chem. 2006;6(5):479-507.
13. Ravindar L, Hasbullah SA, Rakesh KP, Hassan NI. Recent
developments in antimalarial activities of 4-aminoquinoline doi: 10.2174/156802606776743147
derivatives. Eur J Med Chem. 2023;256:115458.
24. Wu YC, Lu MT, Chu PC, et al. Novel 4-aminoquinoline
doi: 10.1016/j.ejmech.2023.115458 analogs targeting the HIF-1α signaling pathway. Future Med

Volume 1 Issue 1 (2024) 103 doi: 10.36922/imo.3442